2seventy bio, Inc. (Nasdaq: TSVT), has announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. “A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,” said Chip Baird, chief executive officer, 2seventy bio.
Read the full article: 2seventy bio Enters into Definitive Agreement to Be Acquired by Bristol Myers Squibb //
Source: https://www.businesswire.com/news/home/20250310482749/en/2seventy-bio-Enters-into-Definitive-Agreement-to-be-Acquired-by-Bristol-Myers-Squibb